Driving Innovation for Pharmaceutical Excellence

At Inke, innovation is the cornerstone of our R&D endeavours. Our dedicated team of professionals, backed by extensive expertise, specializes in the development of cutting-edge Active Pharmaceutical Ingredients.

Inke stands as a beacon of patenting leadership in Active Pharmaceutical Ingredients. Over the past decade, we have emerged as one of the top three European respiratory API manufacturing companies with the highest number of patent filings. With over 125 patent applications, encompassing new synthetic processes, polymorphic forms, and salts, we continue to push the boundaries of innovation in the pharmaceutical industry.

Pioneering API Development

Within our state-of-the-art laboratories, our highly-trained professionals meticulously develop and refine processes tailored to meet the exacting standards of our manufacturing plant.

We pride ourselves on our ability to customize products, including Particle Size Distributions using an accurate micronization technique, to address the unique technical and regulatory requirements of each customer throughout the development and commercialization phases of their FDF Products.

Inke is at the forefront of early market entries, particularly in regions without product patent constraints.

Patented Synthetic Processes

Leveraging patented synthetic processes to provide innovative solutions that offer a competitive edge to our partners.

Novel Polymorphic Forms and Salts

Developing novel polymorphic forms, salts, and cocrystals to enhance API manufacturing.

Robust Patent Portfolio

Our robust patent portfolio, comprising non-infringing or improvement patents, underscores our commitment to pioneering advancements in API manufacturing.

As a testament to our commitment to scientific advancement, Inke participates as a sponsoring exhibitor at the Respiratory Drug Delivery (RDD) Symposia.

Process for Obtaining Stable Micronized Glycopyrronium Bromide for Inhaled Treatment of Respiratory Diseases.

Download RDD Europe 2017. Volume 2, 2017: 243-248.

Comparative Stability Studies Between Air Jet Micronized and Wet Milled Glycopyrronium Bromide Towards

Download Humidity. Respiratory Drug Delivery 2018. Volume 2, 2018: 429-432.

Process for Reducing Amorphous Content on Micronized Indacaterol Maleate for Dry Powder Inhaler Formulations.

Download Respiratory Drug Delivery 2018. Volume 2, 2018: 433-436.

Through the presentation of scientific posters, we share our latest research findings and technological breakthroughs with industry peers and stakeholders, further solidifying our position as a pioneering force in the respiratory field.